Navigation Links
Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
Date:4/11/2011

WHITEHOUSE STATION, N.J., and VIENNA, April 11, 2011 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) recommended suspension of enrollment. Although the trial did not meet the pre-specified futility criteria, the DMC nonetheless recommended suspension of enrollment pending further analyses of the benefit/risk profile of the vaccine candidate. Merck and Intercell plan to provide a further update when analyses have been completed.

About S. aureus

S. aureus is a leading cause of hospital-acquired infections. In addition to bloodstream infections with a mortality rate of up to 35 percent, infections of bone, heart and other inner organs can often lead to serious health complications and death. Today, approximately 50 percent of S. aureus strains isolated in hospitals worldwide are resistant to multiple antibiotics, rendering staphylococcal disease management increasingly difficult and challenging.

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business, including words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," or similar words. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Merck Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the United States and internationally and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2010 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).


'/>"/>
SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
2. Delcath to Update Investors on FDA Meeting
3. TPI Business and Development Profile Updated on OneMedDatabase
4. Dipexium Pharmaceuticals Updates Locilex™ Development Activities and Announces 2011 Milestones
5. NeoStem Provides Results for 2010 and an Update on Recent Activities
6. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
7. Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2010 and to Provide a Business Update
9. Alexza Reports 2010 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
10. NewCardio to Conduct Corporate Update Conference Call on March 29, 2011
11. OXIS International to Hold Business Update Conference Call on March 22
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , March 30, 2017 The topical ... $92.40 billion in 2016, growing at a CAGR of 6.4% ... is will be major end-user in market. While ... forecast period. ... Browse 87 tables and 41 figures, 10 Company profiles ...
(Date:3/30/2017)... -- Research and Markets has announced the addition ... Forecast, By Type (Hemodialysis, Peritoneal Dialysis), By Product (Device, Consumables, ... To 2025" report to their offering. ... The global hemodialysis ... billion by 2025. Home-based dialysis treatment ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... ... energy-based aesthetic devices market to grow at a CAGR of 8.12% ... Aesthetic Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week of March, Chad ... to eligible individuals in the local community. , Colon cancer is the second ... detect colon cancer while it is small, confined and easier to treat. If you ...
(Date:3/29/2017)... ... 29, 2017 , ... In the United States alone, up to 36% of ... types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are ... more effective treatment options, the San Diego Gamma Knife Center offers a ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... Full Contact ... founder of Pet Protect Law that assists dog owners in creating legally-enforceable ... new owners in taking the natural next step to protect their new companion. Says ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS ... Medical Center will serve as the official title sponsor of the Baltimore Women’s Classic, ... 2017, thousands of women will walk or run the course around the Baltimore Inner ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sublime Naturals ... "Spice of Life" or "Wonder Spice", it has been used for thousands of years. ... the East," says Heshelow, author of " Turmeric: How to Use it For Your ...
Breaking Medicine News(10 mins):